Tacrolimus: Clinical Trials

1,022 trials of Tacrolimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

603 completed, 113 terminated, 108 unknown, 70 recruiting. 420 Phase 2, 243 Phase 4, 167 Phase 3, 148 Phase 1, 74 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2420Completed 220, Terminated 64, Recruiting 45, Active not recruiting 30, Unknown 25, Withdrawn 25, Not yet recruiting 7, Enrolling by invitation 3, Suspended 1
Phase 4243Completed 160, Unknown 42, Terminated 19, Recruiting 6, Active not recruiting 5, Withdrawn 5, Enrolling by invitation 3, Not yet recruiting 3
Phase 3167Completed 106, Terminated 19, Recruiting 14, Unknown 13, Active not recruiting 6, Withdrawn 6, Not yet recruiting 2, Enrolling by invitation 1
Phase 1148Completed 87, Terminated 15, Unknown 13, Withdrawn 12, Recruiting 10, Active not recruiting 8, Suspended 2, Not yet recruiting 1
Not applicable74Completed 42, Unknown 14, Terminated 7, Withdrawn 4, Not yet recruiting 3, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1
Early Phase 113Completed 4, Terminated 4, Withdrawn 2, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1

Follow Tacrolimus: new trials by email Literature Review of Tacrolimus trials Research Report on Tacrolimus

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Orca-Q, myeloablative regimen, Tacrolimus - Primary Progressive Multiple Sclerosis, Multiple Sclerosis
Phase 1Not yet recruitingOrca Biosystems, Inc.102027-03-012026-11-13
CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke
CC-101 (f/k/a NR1) Intracerebral Transplantation, Tacrolimus, Sham Surgical Control - Chronic Ischemic Stroke
Phase 2Not yet recruitingClarion Cells, Inc.362027-01-012026-07-17
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm) - Kidney Transplant Recipient
Early Phase 1Not yet recruitingVirginia Commonwealth University202026-12-012026-11-06
Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory Study
Lanoracopan, Anti-thymocyte globulin (ATG), Calcineurin inhibitor (Cyclosporine or Tacrolimus) - Hematologic Malignancies, Haploidentical Peripheral Blood Stem Cell Transplantation
Phase 2Not yet recruitingThe First Affiliated Hospital of Soochow University302026-12-012026-11-09
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Phase 2Not yet recruitingNational Cancer Institute (NCI)1022026-11-182026-11-13
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Phase 2RecruitingCity of Hope Medical Center352026-11-052026-10-08
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease
Phase 2Not yet recruitingMedical College of Wisconsin722026-11-012026-09-08
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Phase 2Not yet recruitingStanford University302026-11-012026-09-30
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
Phase 2Not yet recruitingCase Comprehensive Cancer Center202026-11-012026-09-24
Efficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail Psoriasis
fractional C02 laser, Topical tacrolimus 0.1% ointment - Nail Psoriasis
Not applicableNot yet recruitingCairo University292026-11-012026-11-05
Tacrolimus as Prophylaxis of Post-ERCP Pancreatitis
Tacrolimus, NaCl (placebo) - Post-ERCP Pancreatitis
Phase 4RecruitingAmsterdam UMC, location VUmc5202026-10-162026-11-12
Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation
Tegoprubart, Tacrolimus - Kidney Transplant Rejection
Phase 3Not yet recruitingEledon Pharmaceuticals6202026-10-012026-09-30
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous
Phase 3RecruitingAmgen1592026-10-012026-10-01
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)
Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases
Phase 3RecruitingHannover Medical School1502026-08-192026-10-05
VEL-101 to Prevent Rejection After Kidney Transplantation
Tacrolimus (TAC), VEL-101 - Transplantation, Kidney
Phase 2RecruitingVeloxis Pharmaceuticals1202026-08-182026-09-03
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis
Phase 4Not yet recruitingUniversity of California, San Francisco102026-08-012026-06-03
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Tacrolimus, Early Tacrolimus Taper Strategy - GVHD, Hematopoietic Cell Transplantation (HCT)
Phase 1RecruitingStanford University502026-07-212026-08-17
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser - Vitiligo, Nonsegmental Vitiligo
Not applicableEnrolling by invitationKafrelsheikh University402026-07-012026-11-02
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease
Phase 1RecruitingCity of Hope Medical Center152026-06-122026-11-09
A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks
Tacrolimus, Crisaborole 2% Top Oint - Atopic Dermatitis
Not applicableNot yet recruitingFoundation University Islamabad722026-06-012026-04-09

Showing 20 of 1022. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (126)  ·  Myelodysplastic Syndromes (123)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (107)  ·  Graft vs Host Disease (89)  ·  Leukemia (86)  ·  Hodgkin Disease (81)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (78)  ·  Lymphoma (76)  ·  Lymphoma, Non-Hodgkin (75)  ·  Multiple Myeloma (75)  ·  Myeloproliferative Disorders (58)  ·  Lymphoma, Follicular (54)  ·  Leukemia, Myeloid, Accelerated Phase (50)  ·  Lymphoma, Large B-Cell, Diffuse (50)  ·  Lymphoma, Mantle-Cell (50)

Sponsors

Astellas Pharma Inc (83)  ·  M.D. Anderson Cancer Center (42)  ·  Fred Hutchinson Cancer Center (35)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (34)  ·  Novartis Pharmaceuticals (24)  ·  City of Hope Medical Center (23)  ·  National Cancer Institute (NCI) (17)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (16)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (14)  ·  Veloxis Pharmaceuticals (13)  ·  Medical College of Wisconsin (12)  ·  Seoul National University Hospital (10)  ·  Astellas Pharma Korea, Inc. (9)  ·  Dana-Farber Cancer Institute (9)  ·  Wyeth is now a wholly owned subsidiary of Pfizer (9)

Countries

United States (568)  ·  Germany (86)  ·  France (78)  ·  Canada (73)  ·  China (70)  ·  Spain (62)  ·  South Korea (55)  ·  Italy (51)  ·  United Kingdom (50)  ·  Belgium (39)  ·  Australia (33)  ·  Netherlands (33)  ·  Poland (33)  ·  Brazil (32)  ·  Czechia (31)

Top investigators

Mary Horowitz, MD (5)  ·  Neal Flomenberg, MD (5)  ·  Usama Gergis, MD (5)  ·  Asad Bashey, MD, PhD (4)

Results publications

PMID 36094829, PMID 23438305, PMID 29149958, PMID 34778952, PMID 35007144, PMID 35224732, PMID 40197799, PMID 16407509, PMID 19660021, PMID 19670189, PMID 22471345, PMID 32343796, PMID 32499241, PMID 35230699, PMID 36240296, PMID 39382091, PMID 39513526, PMID 10071354, PMID 10870982, PMID 11003346, PMID 11072057, PMID 11250374, PMID 11267411, PMID 12171484, PMID 12176626, PMID 12176628, PMID 12270445, PMID 12548508, PMID 12944064, PMID 14550808, PMID 14655180, PMID 14720063, PMID 14742989, PMID 14742990, PMID 15061852, PMID 15233820, PMID 15257060, PMID 15660173, PMID 15691272, PMID 15691277, PMID 15753371, PMID 15885236, PMID 15899725, PMID 15919463, PMID 16164651, PMID 16273116, PMID 16468960, PMID 16570006, PMID 16737942, PMID 16771810

NIH funding

P30CA015704 (14), P30CA033572 (10), 2009 (8), U10CA031946 (8), P01CA018029 (7), 2023 (6), P30CA016672 (6), 2008 (5), 2014 (5), 2025 (5), U01HL069294 (5), 2005 (4), P01CA015396 (4), P01CA078902 (4), P01HL036444 (4)